To date, all reported monoclonal antibodies directed toward MUC16 bind to epitopes present on the CA-125 fraction of the glycoprotein, and none is known to bind to the retained extracellular MUC16ecto fraction of the antigen; this retained fraction with independent pro-oncogenic properties remains on the tumor cell surface and therefore represents the most attractive target for immune-based therapies in patients with advanced EOC (61, 70, 71). Here, MUC16 is linked to neoplasm.